Abstract:BACKGROUND: It has been reported that nanosilver-containing biomaterials produce bad biological effects after they directly contact with or are implanted into human body. OBJECTIVE: To investigate whether nanosilver yields potential adverse biological effects on human body and to evaluate its biological safety. DESIGN, TIME AND SETTING: An animal experiment observation was performed at the Medical Device Center of National Institute for the Control of Pharmaceutical and Biological Products from June 2005 to August 2006. MATERIALS: Nanosilver particles and microsilver particles were purchased from Sigma Company, USA. METHODS: Thirty rats were randomly divided into 3 groups, with 5 male and 5 female rats per group: nanosilver, microsilver, and blank control. Nanosilver and microsilver particles were respectively and subcutaneously implanted for subchronic toxicity test. The nanosilver and microsilver groups were given 0.33 g/kg nanosilver and microsilver, respectively. Rats from the blank control group received identical procedure, with the exception of drug application. Four rats were selected from each group for determination of silver content in serum and some organs by plasma mass spectrometry. MAIN OUTCOME MEASURES: serum biochemical indices, organ coefficient, and silver content. RESULTS: There was significant difference in individual organ coefficient between each drug application group and blank control group. But no significant difference in absolute mass was found between each drug application and the blank control group. These findings suggested no clinical significance of organ coefficient. Other organ coefficients were in the normal range, and there was no significant difference between each drug application group and the blank control group. Patho-histological changes related to toxicity were not found. Rats from the nanosilver group did not show toxic reaction. CONCLUSION: Nanosilver produces potential adverse biological effects after implanted into human body.

Biodistribution of nanosilvers in mice

Bio-distribution and Bio-Availability of Silver and Gold in Rat Tissues with Silver/gold Nanorod Administration

Biodistribution and toxicity of intravenously administered silica nanoparticles in mice

Distribution, Translocation and Accumulation of Silver Nanoparticles in Rats.

Nanosilver and microsilver distributions in several tissues of rats

Kinetics of Silver Accumulation in Tissues of Laboratory Mice after Long-Term Oral Administration of Silver Nanoparticles

Evaluation of the biological fate and the transport through biological barriers of nanosilver in mice.

Bioavailability and Distribution of Nanosilver after Oral Administration in Rats

Acute Toxic Effects and Gender‐related Biokinetics of Silver Nanoparticles Following an Intravenous Injection in Mice

Biodistribution and organ oxidative damage following 28 days oral administration of nanosilver with/without coating in mice

[Biotoxicology and Biodynamics of Silica Nanoparticle].

Nanosilver Subchronic Toxicity and Silver Distribution in Different Rat Tissues

The biodistribution and transformation of nanoparticulate and ionic silver in rat organs in vivo

Acute Toxic Effects of Nanosilver Via Tail Intravenous Injection in Mice

Comparisons of the biodistribution and toxicological examinations after repeated intravenous administration of silver and gold nanoparticles in mice

An insight into silver nanoparticles bioavailability in rats.

In vivo distribution of silicon nanoparticles and toxicity tests

The progress of silver nanoparticles in the antibacterial mechanism, clinical application and cytotoxicity

Brain-targeted distribution and high retention of silver by chronic intranasal instillation of silver nanoparticles and ions in Sprague-Dawley rats.

Determing the biodistribution of nano-Fe2O3-Glu in mice by 59Fe tracer and preparation

Bioaccumulation And Toxicity Of Carbon Nanoparticles Suspension Injection In Intravenously Exposed Mice